Research programme: Alzheimer's disease therapeutics - Celera Diagnostics/Merck

Drug Profile

Research programme: Alzheimer's disease therapeutics - Celera Diagnostics/Merck

Latest Information Update: 16 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celera Diagnostics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 10 Aug 2007 Preclinical development is ongoing
  • 01 Jan 2006 Celera Diagnostics has been acquired by Celera Genomics Group
  • 07 Sep 2005 Celera and Merck have extended their collaboration in the development of therapeutic and diagnostics products for Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top